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Executive summary
† Surgical and interventional treatment for mitral regurgitation
(MR) requires a multidisciplinary approach. Experienced opera-
tors in high volume centers with a dedicated Heart Team obtain
best outcomes.
† Surgical repair is the reference standard treatment in primary MR.
Timely surgery is associated with excellent outcome and restor-
ation of normal life expectancy. Percutaneous procedures should
be reserved for high-risk or inoperable symptomatic patients.
† The choice of treatment in secondary MR is more controversial:
– Surgical correction can improve symptoms and quality of life,
and reverse left ventricular (LV) remodelling in selected pa-
tients. However, a clear prognostic benefit in comparison
with optimal medical therapy has not been demonstrated.
Undersized annuloplasty might offer a satisfactory result if
performed before the onset of severe LV dilatation and in
the absence of echocardiographic predictors of post-
operative residual or recurrent MR. Otherwise, mitral valve
(MV) replacement with preservation of the sub-valvular
apparatus is preferable.
– Percutaneous edge-to-edge (EE) repair for secondary MR is a
low-risk option to reduce symptoms and induce reverse LV
remodelling but is commonly associated with residual and re-
current MR. The procedure should be reserved for patients
who have significant symptoms despite optimal heart failure
therapy (including cardiac resynchronisation where appropri-
ate), are judged to be at excessive risk for MV surgery by a
Heart Team, fulfil the echocardiographic criteria of eligibility,
and do not have existing comorbidities to preclude the
benefits of correction or reduction of MR.
† Ongoing trials in patients with isolated secondary MR will define
whether percutaneous EE repair has a significant role in the
management of heart failure.
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† Randomized studies are needed to clarify whether correction of
MR in high-risk patients provides clinical and prognostic benefit in
comparison with optimal medical therapy.
Introduction
Mitral regurgitation (MR) has a prevalence of 2% in the general
population and is even more common in the elderly.1 Organic
(or primary) MR arises as a result of pathology affecting one or
more components of the mitral valve (MV) apparatus, whereas func-
tional (or secondary) MR is a consequence of annular dilatation and
geometrical distortion of the sub-valvular apparatus secondary to
left ventricular (LV) remodelling and dyssynchrony, most usually as-
sociated with cardiomyopathy or coronary artery disease.
Primary MR is usually a consequence of degenerative disease,
which may remain asymptomatic for many years—intervention
has generally been withheld until the onset of symptoms or evi-
dence of haemodynamic decompensation. However, treatment al-
gorithms have been redefined in recent years as a result of the
excellent outcomes of surgical repair. International guidelines now
recommend risk stratification and earlier intervention when the
probability of durable repair is high and when surgery can be under-
taken by experienced teams with high repair rates and low operative
mortality and morbidity.2
Secondary MR has worse prognosis and treatment options are
complex, including optimized medical therapy, biventricular pacing,
valve surgery (with or without revascularization), long-term LV as-
sist devices or cardiac transplantation. Surgery is challenging with in-
ferior outcomes than in primary MR and the indications and choice
of technique are not supported by robust evidence.2
In recent years, a variety of approaches to percutaneous treat-
ment of primary and secondary MR has emerged. The most widely
adopted has been the edge-to-edge (EE) procedure with promising
results in large registries and small randomized trials. Meanwhile,
numerous alternative technologies (including percutaneous MV
replacement) are in development.
Herein, a Task Force of the European Society of Cardiology (ESC)
Working Groups on Cardiovascular Surgery and Valvular Heart
Disease outline the indications and limitations of surgical and percu-
taneous treatment of MR, and propose recommendations for case
selection, team working and outcome monitoring.
The Heart Team
Amultidisciplinary Heart Team (interventional cardiologists, cardiac
surgeons, anaesthetists, imaging, and heart failure specialists) should
evaluate the pros and cons of surgical, percutaneous and con-
servative approaches in all high-risk patients with MR, assessing
the risk–benefit ratio of each option whilst incorporating relevant
comorbidities and individualized life expectancy. The possible futility
of intervention in very high-risk subjects must also be considered—
some will not benefit from surgical or percutaneous intervention
and conservative management (and possible palliative care) is
more appropriate.
Risk assessment is fundamental to decision-making, particularly
when considering a procedure other than the reference standard.
Percutaneous intervention in MR should currently be reserved for
high-risk or inoperable patients. While most procedural risk scores
discriminate between high and low risk, they were not developed in
large cohorts with valvular heart disease and are poorly calibrated in
high-risk subjects.3 Definitions of ‘high surgical risk’ and the ‘inoper-
able patient’ remain elusive and significantly influenced by surgeon
and centre experience.4,5 Established risk scores (e.g. STS, Euro-
score) should be utilized in conjunction with other factors (e.g.
frailty, porcelain aorta) as recommended by the VARC-2 consensus
document.6
A tailored approach for individual patients remains appropriate in
the absence of guidelines for the conduct of Heart Team activity and
an evidence-base to demonstrate its effectiveness.3 Research to
confirm the intuitive benefits of the Heart Team approach is re-
quired, potentially by the ESC or European Union using centralized
audit resources.
Imaging assessment
Detailed (usually transoesophageal) echocardiography (TEE) is
essential to quantitate MR (Table 1, Figure 1), define anatomical suit-
ability for surgical or percutaneous MV repair and demonstrate the
presence of LV/left atrial thrombi or active endocarditis which might
contraindicate intervention or suggest an alternative approach.
In patients with primary MR suitable for surgery, all scallops of the
posterior and anterior leaflets should be carefully assessed with
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Table 1 Echocardiographic criteria for the definition
of severe mitral regurgitation
Qualitative
Mitral valve morphology Flail leaflet/ ruptured papillary muscle
Colour flow regurgitant jet Very large central or eccentric jet
adhering, swirling and reaching the
posterior wall of the left atrium
Continuous wave signal of
regurgitant jet
Dense/triangular
Flow convergence zone Largea
Semi-quantitative
Vena contracta width (mm) ≥7 (.8 for biplane)b
Pulmonary vein flow Systolic flow reversal
Inflow E-wave dominant ≥1.5 m/sc
TVI mitral/TVI aortic ≥1.4
Quantitative








Left ventricle, left atrium
TVI, time-velocity integral; EROA, effective regurgitant orifice area.
aNyquist limit 50–60 cm/s.
bAverage between apical four- and two-chamber views.
cIn the absence of mitral stenosis or other causes of elevated left atrial pressure.
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comprehensive description of the lesion(s), their location and the
presence of annular calcification.
When surgery is considered in secondary MR, echocardiographic
LV parameters are mandatory (volume, ejection fraction, and spher-
icity index) accompanied by assessment of geometric MV distortion
(tenting area, coaptation depth, leaflet angles, and inter-papillary
muscle distance). Numerous predictors of recurrent MR after
undersized annuloplasty have been identified2 (Table 2, Figures 2
and 3) and their presence should lead to consideration of MV re-
placement as a more durable solution.
Transoesophageal echocardiography is also essential to confirm
anatomical eligibility for percutaneous EE repair. No specific
guidelines are currently available and the EVEREST II trial anatom-
ical inclusion criteria are the principal reference (Table 3). Percu-
taneous treatment outwith these criteria (including pronounced
flail gap or width, commissural MR, advanced LV remodelling, ana-
tomic cleft, and asymmetric tethering) is now common, although
certain anatomical conditions predict failure or suboptimal out-
come (Table 4).
Figure 1 Three-dimensional transoesophageal echocardiographic evaluation of the mitral valve. (A) 08 plane illustrating left left atrial dilatation
and leaflet configuration. (B) 608 plane demonstrating an eccentric anteriorly directed jet of moderate–severe mitral regurgitation. (C) Three-
dimensional surgical view from the left atrium demonstrating mitral valve orifice in mid-diastole. (D) Three-dimensional view with colour flow
Doppler confirming eccentric anteriorly directed jet of moderate–severe mitral regurgitation. Images courtesy of Dr Ronak Rajani, St Thomas’
Hospital, London, UK.
Table 2 Echocardiographic predictors of repair failure
or recurrent mitral regurgitation after undersized
annuloplasty in secondary mitral regurgitation
Coaptation depth .1 cm
Systolic tenting area .2.5 cm2
Posterior mitral leaflet angle .458
Distal anterior mitral leaflet angle .258
LV end-diastolic diameter .65 mm
LV end-systolic diameter .51 mm
End-systolic inter-papillary muscle distance .20 mm
Systolic sphericity index .0.7
LV, left ventricular.
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There is no evidence-based medical therapy for patients with pri-
mary MR and minimal or no symptoms. Whilst b-blockers and
angiotensin converting enzyme (ACE) inhibitors may palliate symp-
toms once heart failure has developed, they should not be used to
postpone the need for intervention.2
Surgery
Mitral valve repair is the preferred surgical treatment for severe de-
generative MR with significant advantages over MV replacement.2,7,8
The main goals—restitution of physiological leaflet motion, achieve-
ment of adequate leaflet coaptation and annular stabilisation with
maintenance of an adequate mitral orifice2—can be achieved using
a variety of isolated or combined techniques (leaflet resection, im-
plantation of artificial chordae, chordal transposition/transfer,
edge-to-edge technique, annuloplasty using a prosthetic ring or
band) according to the type and location of the mitral lesion(s).
Nowadays, .95% of degenerative MV lesions can be successfully
repaired in expert centres.9 – 11 Although the risk of repair failure
increases in patients with anterior or bileaflet prolapse,12 advanced
myxomatous disease, annular calcification, or failure to undertake
ring annuloplasty,13 freedom from reoperation is .90% at 10 years
and .80% at 20 years.12–14
Surgical outcomes depend on pre-operative status, mechanism of
MR, technique of repair, and experience of the centre and surgeon.
Centres with large experience in MV repair achieve hospital mortal-
ity,1%, very low rates of major adverse events and good long-term
results13–17 and patients should be referred to experienced centres
to maximize the likelihood of a durable repair (particularly if a policy
of ‘early repair’ is adopted).18,19 Long-term survival and quality of life
after timely MV repair mirror the age-matched general population.
In contrast, late survival is reduced if MV repair is carried out in pa-
tients with congestive heart failure, reduced LV ejection fraction,
pulmonary hypertension, or atrial fibrillation.2,13,20
Percutaneous intervention
Several new transcatheter mitral devices are currently under inves-
tigation, although the MitraClipw System (Abbott Vascular, CA,
USA), approved for use in high risk or inoperable patients with
severe MR and suitable anatomic criteria21 is the only one widely
available, with .30 000 implantations performed worldwide.
Figure 2 Contrast-enhanced ECG-gated cardiac computed tomographic evaluation of the mitral valve. (A) En face view illustrating segmental
anatomy of anterior (A1–A3) and posterior (P1–P3) valve leaflets. (B–D) Corresponding multiplanar images of individual scallops, their relation
to the left ventricle and angulation relative to the mitral valve plane. MVTH, mitral valve tenting height. Image courtesy of Dr Ronak Rajani,
St Thomas’ Hospital, London, UK.
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Percutaneous EE repair with this device is safe in degenerative MR
with low rates of procedural and 30-day mortality,22–24 complica-
tions (stroke, bleeding, tamponade, or resuscitation)23–26 and short
mean hospital stay.23,27 One-year survival is 80%24 mirroring the ad-
vanced age and multiple comorbidities of the populations studied.
Post-procedural mitral stenosis is very rare and rates of clip detach-
ment ,2%.28 Acute procedural success rate (final MR grade ≤2) is
80–85% and maintained at 1- and 4-year follow-up.22,24,29
Comparisons of surgery and percutaneous intervention in primary mitral
regurgitation
In the EVEREST II study,22 279 patients with Grades 3–4 MR were
randomized 2 : 1 to undergo percutaneous EE repair or surgery
(repair or replacement). Most had degenerative MR, relatively low-
risk profile, moderate LV dysfunction, and strict inclusion criteria
regarding LV size–function and MV anatomy. Percutaneous repair
was associated with a higher rate of MR requiring repeat surgery
(20.4 vs. 2.2% at 1 year; 24.8 vs. 5.5% at 4 years, both P,
0.001)22,29 and reduced efficacy as defined by freedom from death,
surgery for MV dysfunction or MR Grades 3–4 [55 vs. 73% (P ¼
0.007) at 1 year; 40 vs. 53% (P ¼ 0.07) at 4-years]. Reported im-
provements in safety with the percutaneous technique were driven
by the higher need for blood transfusion in the surgical arm.
It should be noted that EVEREST II patients were significantly dif-
ferent from those currently treated in Europe who mainly have sec-
ondary MR, severe LV dysfunction/remodelling, congestive heart
failure, multiple comorbidities, and higher surgical risk. Moreover,
the outcome data refer to the early stage of procedural experience
and high volume centres are experiencing rapidly improving
outcomes.
Summary statements: primary mitral regurgitation
† Surgery remains the first option in primary MR with very low
operative mortality and established efficacy and durability in high
volume centres.
† Percutaneous EE repair is an alternative in symptomatic
inoperable and high-risk patients. Early mortality following
percutaneous treatment in this high-risk subgroup has been high
(up to 9%)4,24,30 and .50% of patients have been left with
residual or recurrent ≥2/4 MR at 1 year.5,24
† Properly designed randomized studies are needed to establish
the best therapeutic option in this high-risk subset.
Secondary mitral regurgitation
Medical therapy
Medical therapy (ACE inhibitors, b-blockers, and aldosterone an-
tagonists) is mandatory in secondary MR.31 Diuretics may be re-
quired for fluid overload and vasodilators have a role in acute
haemodynamic decompensation. Cardiac resynchronisation ther-
apy should be considered in appropriate candidates.31
Surgery
The best surgical treatment for secondary MR remains controver-
sial.32–34 Mitral repair performed with an undersized rigid complete
ring to restore leaflet coaptation and valve competence is the
Figure 3 Use of contrast-enhanced ECG-gated cardiac com-
puted tomography in reconstructed end-systolic phase to facilitate
mitral valve assessment. White lines indicate planes used to derive
sphericity index (X/Y), black arrowed line ¼ inter-papillary muscle
distance. Image courtesy of Dr Ronak Rajani, St Thomas’ Hospital,
London, UK.
Table 3 Key anatomic eligibility criteria for
percutaneous edge-to-edge repair (EVEREST II)
Moderate-to-severe MR (Grade 3/4 or more)
Pathology in A2–P2 zone
Coaptation length ≥2 mm
Coaptation depth ,11 mm
Flail gap ,10 mm
Flail width ,15 mm
Mitral valve orifice area .4 cm2
Mobile leaflet length .1 cm









Severe left ventricular remodelling
Large (.50%) inter-commissural extension of regurgitant jet
Severe myxomatous degeneration with multi-scallop prolapse
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reference standard35 and can be performed with acceptable peri-
operative risk in carefully selected patients with secondary MR
and poor LV function.36 More advanced leaflet tethering predicts re-
pair failure and recurrent MR37,38 and concomitant techniques to
improve durability (secondary chordal resection, suturing of the
posteromedial papillary muscle to the aorto-mitral continuity, in-
farct plication, papillary muscle imbrication, and posterior LV restor-
ation) have been described in small, non-randomized, and
observational studies.39 – 41 Restrictive annuloplasty was recently
compared with chordal-sparing MV replacement in a randomized
study of patients with secondary MR of ischaemic origin and demon-
strated no advantage with regard to LV end-systolic volume index or
1-year mortality.34 However, the trial was underpowered for mor-
tality at 1 year and included patients with pre-operative predictors
of repair failure. Further studies are required to determine whether
selected patients with secondary MR benefit from surgical repair.
Moreover, no study has convincingly demonstrated a survival
benefit compared with medical therapy42 which argues against sur-
gical intervention in asymptomatic patients and poses a complex
surgical decision in high-risk cases. Recurrent MR is the main disad-
vantage37,38 which may underlie the lack of observed survival bene-
fit—several predictors have been identified and should be
considered during patient selection (Table 2).2,43,44
Percutaneous intervention
Secondary MR is currently the most common indication for percu-
taneous EE repair, accounting for 65–75% of patients.23,25,27,45 The
ACCESS-EU registry23 enrolled 393 patients with secondary MR,
severe LV dysfunction, and congestive heart failure—mortality
was 3% at 30 days and 17% at 1 year with significant complications
(stroke, resuscitation, and tamponade) in 1–2% of cases. Efficacy
was similar to previous findings in degenerative MR with residual
MR Grades 3–4 in 8 and 22% at discharge and 12-month follow-up,
respectively. The majority (69%) were in NYHA class I/II at 12
months with demonstrable reverse LV and left atrial remodelling
but residual MR Grade 2+ in almost 50%.46,47 Similar results have
been reported in other series.30,48,49
Comparisons of surgery and percutaneous intervention in secondary mitral
regurgitation
Direct comparisons between percutaneous EE repair and surgery in
secondary MR are difficult since patients treated with either strategy
are significantly different. One small non-randomized series re-
ported higher efficacy of surgery compared with percutaneous
intervention (freedom from MR ≥3+ at 1 year 94 vs. 79%, P ¼
0.01).46 In contrast, post hoc analysis of the EVEREST II trial demon-
strated equivalence of the two strategies in this setting.22,29 How-
ever, in the absence of a medical therapy control group, it is not
possible to establish whether either treatment has positive impact
on survival—ongoing randomized studies will address this question.
Surgery following failed percutaneous EE repair can be challen-
ging as a consequence of clip-induced scarring and fibrosis
(Figure 4).50,51 Whilst this may be acceptable in high-risk patients
with secondary MR, this is not the case in low-risk primary MR
patients—percutaneous techniques are not appropriate in this
population.
Summary statements: secondary mitral regurgitation
† Medical therapy is paramount in secondary MR.
† The role of surgery is controversial, particularly when
concomitant revascularization is not an option,2 owing to
significant operative mortality, high rates of recurrent MR, and
absence of proven survival benefit.42,52
† Percutaneous EE repair is a lower risk option to reduce
symptoms and induce reverse LV remodelling but commonly
associated with residual and recurrent MR. Thus, it should only
be considered in addition to optimal medical therapy (including
cardiac resynchronization where appropriate) in patients who
are symptomatic, fulfil anatomical criteria, and judged high-risk
or inoperable by the Heart Team.
Recommendations for outcome
assessment
Head-to-head comparison of surgical and percutaneous interven-
tions is not possible since they are used as complementary rather
than alternative techniques in different populations. Ongoing rando-
mized studies will require careful design and interpretation to en-
able future evidence-based decision-making:
† Endpoints should be rigorously pre-defined with adjustment for
cross-over.
† Outcome definitions and nomenclature should adhere to inter-
national recommendations (including those designed for percu-
taneous valve interventions).6,53,54
† Specific echocardiographic criteria should be defined and
validated.
† Safety and efficacy should be evaluated jointly by cardiologists
and cardiac surgeons.
– Safety has a major role in driving the choice between surgical
and percutaneous approaches—clinically relevant endpoints
should be used to compare strategies.
– Patient-reported outcome measures relating to quality of life
should be incorporated alongside conventional clinical end-
points and assessed routinely.
Figure 4 Excised mitral valve (ventricular view) after implant-
ation of two edge-to-edge clips.
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– The components of each endpoint should be related and of
similar clinical importance.
– Procedure-specific complications should not be used when
their clinical implications are unclear. For example, the EVER-
EST II trial suggested superiority of percutaneous EE repair
since these patients received fewer blood transfusions than
surgical controls.22 Although blood transfusion is a marker
of adverse clinical outcome, use of conglomerate endpoints
whichmeasure different but unrelated aspects of the same dis-
ease process should be avoided.
– Efficacy should be measured at pre-defined long-term follow-
up—most recurrent MR arises during the first post-operative
year55,56 and early outcomes should be interpreted with
caution.
– The goal of MV repair should be defined to achieve consistent
outcome reporting. For example, residual Grade 2 MR is un-
satisfactory following surgical repair,55 but often classified as
procedural success following percutaneous intervention (des-
pite negative prognostic impact).47,55
– Minor changes of regurgitant volume or LV ejection function
should not be used to argue the superiority of a particular ap-
proach—there are no data to demonstrate their impact on
clinical outcome.22,57
Future perspectives
Percutaneous interventions offer potential for beating-heart MV re-
pair and replacement under physiological conditions without need
for cardiopulmonary bypass. Beyond percutaneous EE repair, trans-
catheter chordal replacement, and indirect annuloplasty (using cor-
onary sinus devices, radiofrequency-mediated annular remodelling,
and cinching devices) are in various stages of development.58,59
These technologies have no surgical equivalent and their efficacy
needs to be proven. Conversely, percutaneous direct annuloplasty
reproduces surgical techniques and can be achieved with annular pli-
cation60 or commissure-to-commissure implant.61
Techniques for percutaneous MV replacement are progressing62
and need to encompass large device delivery, anchoring without im-
pinging the LV outflow tract or other adjacent structures, avoidance
of paravalvular regurgitation, and maintained durability.
Three-dimensional echocardiography, fusion imaging, and com-
puter modelling will guide device selection, procedural efficacy,
and safety. Education of mitral intervention specialists will be vital
to ensure appropriate patient selection, procedural skills, and peri-
operative management. Further evolution of percutaneous tech-
nologies and advanced imaging will require regulatory approval
and appropriate reimbursement.
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